Psychoneuroendocrinology
Volume 35, Issue 3 , Pages 350-363 , April 2010

Day-to-day co-variations of psychological and physical symptoms of the menstrual cycle: Insights to individual differences in steroid reactivity

Received 8 June 2009 ,Revised 14 July 2009 ,Accepted 16 July 2009.

References 

  1. Ace CI, Okulicz WC. Differential gene regulation by estrogen and progesterone in the primate endometrium. Mol. Cell Endocrinol. 1995;115:95–103
  2. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th ed.. Washington, DC: American Psychiatric Association; 1994;
  3. Asarian L, Geary N. Estradiol enhances cholecystokinin-dependent lipid-induced satiation and activates estrogen receptor-α-expressing cells in the nucleus tractus solitarius of ovariectomized rats. Endocrinology. 2007;148:5656–5666
  4. Bixo M, Andersson A, Winblad B, Purdy RH, Bäckström T. Progesterone, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res. 1997;764:173–178
  5. Bloch M, Schmidt PJ, Rubinow DR. Premenstrual syndrome: evidence for symptom stability across cycles. Am. J. Psychiatry. 1997;154:1741–1746
  6. Bryk AS, Raudenbush SW. Hierarchical Linear Models: Application and Data Analysis Methods. Newbury Park: Sage Publications; 1992;
  7. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav. Immun. 2007;21:153–160
  8. Dawood YM. Primary dysmenorrhea: advances in pathogenesis and management. Obstet. Gynecol. 2006;108:428–441
  9. Di Leo A, Barone M, Maiorano E, Tanzi S, Piscitelli D, Marangi S, et al. ER-β expression in large bowel adenomas: implications in colon carcinogenesis. Dig. Liver Dis. 2008;40:260–266
  10. Doyle C, Swain Ewald HA, Ewald PW. Premenstrual syndrome: an evolutionary perspective on its causes and treatment. Perspect. Biol. Med. 2007;50:181–202
  11. Dubrovsky BO. Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2005;29:169–192
  12. Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W, et al. Cortical γ-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder. Arch. Gen. Psychiatry. 2002;59:851–858
  13. Freeman EW. Treatment of depression associated with the menstrual cycle: premenstrual dysphoria, postpartum depression, and the perimenopause. Dialogues Clin. Neurosci. 2002;4:177–191
  14. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res. 1996;65:97–106
  15. Freeman EW, Sondheimer S, Weinbaum PJ, Rickels K. Evaluating premenstrual symptoms in medical practice. Obstet. Gynecol. 1985;65:500–505
  16. Gorodeski GI. cGMP-dependent ADP depolymerization of actin mediates estrogen increase in cervical epithelial permeability. Am. J. Cell Physiol. 2000;279:C2028–C2036
  17. Grandien K. Determination of transcription start sites in the human estrogen receptor gene and identification of a novel, tissue-specific, estrogen receptor-mRNA isoform. Mol. Cell Endocrinol. 1996;116:207–212
  18. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology. 2003;28:1–23
  19. Halbreich U, O’Brien S, Eriksson E, Bäckström T, Yonkers KA, Freeman EW. Are there differential symptom profiles that improve in response to different pharmacological treatments of Premenstrual Syndrome/Premenstrual Dysphoric Disorder?. CNS Drugs. 2006;20:523–547
  20. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and γ-aminobutyric acid levels in major depression determined using proton magnetic resonance spectrometry. Arch. Gen. Psychiatry. 2007;64:193–200
  21. Hikima T, Maibach HI. Gender differences of enzymatic activity and distribution of 17β-hydroxysteroid dehydrogenase in human skin in vitro. Skin Pharmacol. Physiol. 2007;20:168–174
  22. Howards PP, Schisterman EF, Wactawski-Wende J, Reschke JE, Frazer AA, Hovey KM. Timing clinical visits to phases of the menstrual cycle by using a fertility monitor: the BioCycle study. Am. J. Epidemil. 2009;169:105–112
  23. Kelly RW, King AE, Critchley OD. Cytokine control in human endometrium. Reproduction. 2001;121:3–19
  24. Kiesner J. Physical characteristics of the menstrual cycle and premenstrual depressive symptoms. Psychol. Sci. 2009;20:763–770
  25. Kimbro SK, Duschene K, Willard M, Moore JA, Freeman S. A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment. Mol. Bio. Rep. 2008;35:23–27
  26. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 1986;232:1004–1007
  27. Mannix LK. Menstrual-related pain conditions: dysmenorrhea and migraine. J. Womens Health. 2008;5:879–891
  28. Martin VT. New theories in pathologenesis of menstrual migraine. Curr. Pain Headache Rep. 2008;12:453–462
  29. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685–697
  30. Oh H, Smart RC. An estrogen receptor pathway regulates the telogen–anagen hair follicle transition and influences epidermal cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 1996;93:12525–12530
  31. Perlman WR, Tomaskovic-Crook E, Montague DM, Webster MJ, Rubinow DR, Kleinman JE, et al. Alteration in estrogen receptor α mRNA levels in frontal cortex and hippocampus of patients with major mental illness. Biol. Psychiatry. 2005;58:812–824
  32. Puder JJ, Blum CA, Mueller B, De Geyter C, Dye L, Keller U. Menstrual cycle symptoms are associated with changes in low-grade inflammation. Eur. J. Clin. Invest. 2006;36:58–64
  33. Rapkin A. A review of treatment of premenstrual syndrome & premenstrual dysphoric disorder. Psychoneuroendocrinology. 2003;28:39–53
  34. Rubinow DR, Hoban CM, Grover GN, Galloway SD, Roy-Byrne P, Andersen R, et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am. J. Obstet. Gynecol. 1988;158:5–11
  35. Rubinow DR, Schmidt PJ. Gonadal steroids, brain, and behavior: role of context. Dialogues Clin. Neurosci. 2002;4:123–137
  36. Schechter D, Bachmann GA, Vaitukaitis J, Phillips D, Saperstein D. Perimenstrual symptoms: time course of symptom intensity in relation to endocrinologically defined segments of the menstrual cycle. Psychosom. Med. 1989;51:173–194
  37. Schmidt F, Grulich-Henn J, Heirich UE, Bettendorf M. Mucosal cytology in the determination of the pubertal status in girls. Horm. Res. 2002;58:223–228
  38. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N. Eng. J. Med. 1998;338:209–216
  39. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch. Womens Ment. Health. 2003;6:203–209
  40. Strine TW, Chapman DP, Ahluwalia IB. Menstrual-related problems and psychological distress among women in the United States. J. Womens Health. 2005;14:316–323
  41. Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, et al. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res. 2008;10:R46
  42. Takeda T, Tasaka K, Sakata M, Murata Y. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese women. Arch. Womens Ment. Health. 2006;9:209–212
  43. Waeber C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology. 2005;64:S9–S15
  44. Williams M, Cunliffe WJ. Explanation for premenstrual acne. Lancet. 1973;302:1055–1057
  45. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol. Med. 2002;32:119–132

PII: S0306-4530(09)00239-X

doi: 10.1016/j.psyneuen.2009.07.011

Psychoneuroendocrinology
Volume 35, Issue 3 , Pages 350-363 , April 2010

Article Tools

* Image Usage & Resolution